Low expression levels of AREG and EREG associated with KRAS mutations might indicate a tumor that is less dependent on EGFR and is therefore particularly prone to developing resistance to anti-EGFR MoAbs [6,8,10,20,21]. Here, KRAS is linked to neoplasm.